D

이연제약

102460KOSPI의약품 제조업

39.8 / 100

Reference Date: 2026-06-10

Financial Score8.5 / 40
News Sentiment18.3 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is undervalued vs. peers but the high debt ratio poses financial risk. Declined 10.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Il Yeon Pharm is a specialized pharmaceutical company established in 1964, focusing on the manufacturing and sales of prescription drugs, original pharmaceuticals (e.g., CT contrast agent 'Optirey'), and bulk drugs. Its Chungju facility, certified for biopharmaceutical production and CMO services, supports new drug pipeline development through a production-platform-based R&D model. However, as of 2024, the company reported sales of 145.9 billion won, an operating loss of 30.3 billion won, and a net loss of 29.6 billion won, indicating the need for improved profitability.

Number of Employees

457people

Average Salary

76.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 11.934.0Point
PBR
0.84Industry Average 0.894.0Point

In line with industry avg

ROE
-12.60Industry Average 4.010.0Point

Well below industry avg

Debt Ratio
46.08Industry Average 12.430.0Point

3.7x industry avg (risky)

Trend 2023~20250.5 / 10 points
Revenue Growth Rate
0.5 / 3

Avg ▼1.7% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼19193.7% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -3.2% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 2Neutral 1Negative 0Average Sentiment Score 73.3

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 10,010Won52-week high 13,75052-week low 9,780
1-month return1.0Point

1m -10.94% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral기업지배구조보고서공시2026-06-01
  • Neutral분기보고서 (2026.03)2026-05-15